Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (NCT07357740) titled 'A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes' on Jan. 21.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Novo Nordisk A/S
Condition:
Diabetes Mellitus, Type 2
Intervention:
Drug: CagriSema
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: August 27, 2026
Target Sample Size: 400
Countries of Recruitment:
Denmark
Slovakia
Denmark
Slovaki...